Published in:
Echocardiography, 37 (2020) 4, Seite 536-545
Language:
English
DOI:
10.1111/echo.14625
ISSN:
0742-2822;
1540-8175
Origination:
Footnote:
Description:
AbstractIntroductionCoronary vascular dysfunction, as assessed by coronary flow reserve (CFR) in the left anterior descending coronary artery, is found in various conditions including end‐stage chronic kidney disease (CKD). Currently, we investigated the associations of CFR with echocardiographic indices of systolic and diastolic cardiac function and identified independent predictors of CFR in hemodialysis patients.MethodsEnd‐stage CKD patients treated with hemodialysis (n = 29) without known cardiovascular disease were recruited from a Hemodialysis Unit in Northwestern Greece. A thorough echocardiographic evaluation including CFR measurement following dipyridamole infusion was performed in all participants. Arterial stiffness was assessed by measurement of carotid–femoral pulse wave velocity and aortic augmentation index.ResultsThe mean age of the patients was 63 years, and mean duration of hemodialysis was 2.9 years. CFR was 1.60 ± 0.37 while dipyridamole caused a significant increase in E'sep, Slat, E'lat, and Stroke volume (P < .05 for all). Independent predictors of CFR were posterior wall thickness (B −0.408, P = .013) and dipyridamole‐induced changes in Tei index (B −0.425, P = .007). A severely decreased CFR < 1.5 was observed in 52% of the patients. E/E' ratio (B 10.84, P = .014) was the single independent predictor of severely decreased CFR.ConclusionsIn end‐stage CKD patients on hemodialysis without known cardiovascular disease, impaired coronary vascular function was prevalent and related to increased left ventricular wall thickness, increased filling pressures, and dipyridamole‐induced deteriorated myocardial function independently of the presence of wall‐motion abnormalities. Further studies are required to clarify the prognostic role of dipyridamole‐induced cardiac changes in hemodialysis patients.